000			03447nam a22004217a 4500
008			220926s20222022 xxu||||| |||| 00| 0 eng d
022			_a0033-0620
024			_a10.1016/j.pcad.2022.06.009 [doi]
024			_aS0033-0620(22)00070-6 [pii]
040			_aOvid MEDLINE(R)
099			_a35777433
245			_aInitiation of anti-hypertensive drugs and outcomes in patients with heart failure with preserved ejection fraction and persistent hypertension.
251			_aProgress in Cardiovascular Diseases. 2022 Jun 28
252			_aProg Cardiovasc Dis. 2022 Jun 28
253			_aProgress in cardiovascular diseases
260			_c2022
260			_fFY2022
260			_p2022 Jun 28
265			_saheadofprint
266			_d2022-09-26
501			_aAvailable in print through MWHC library: 2004 - 2006
520			_aBACKGROUND: National heart failure (HF) guidelines recommend that in patients with HF with preserved ejection fraction (EF;HFpEF) and hypertension, systolic blood pressure (SBP) should be maintained below 130 mmHg. The objective of the study is to examine the association between initiation of anti-hypertensive drugs and outcomes in patients with HFpEF with persistent hypertension.
520			_aCONCLUSIONS: Among hospitalized older patients with HFpEF with uncontrolled hypertension, the initiation of therapy with anti-hypertensive drugs was not associated with all-cause mortality or hospital readmission. Copyright Published by Elsevier Inc.
520			_aMETHODS: Of the 8873 hospitalized patients with HFpEF (EF >=50%) with a history of hypertension without renal failure in Medicare-linked OPTIMIZE-HF, 3315 had a discharge SBP >=130 mmHg, of whom 1971 were not receiving anti-hypertensive drugs, thiazides and calcium channel blockers, before hospitalization. Of these, 366 received discharge prescriptions for those drugs. We assembled a propensity score-matched cohort of 365 pairs of patients initiated and not initiated on anti-hypertensive drugs, balanced on 37 baseline characteristics. Hazard ratios (HR) and 95% confidence intervals (CI) for outcomes associated with anti-hypertensive drug initiation were estimated in the matched cohort.
520			_aRESULTS: Matched patients (n = 730) had a mean age of 78 years; 67% were women and 17% African Americans. During 6 (median 2.5) years of follow-up, 66% of the patients died and 45% had HF readmission. HRs (95% CIs) for all-cause mortality at 30 days, 12 months and 6 years associated with anti-hypertensive drug initiation were 0.64 (0.30-1.36), 0.70 (0.51-0.97), and 0.95 (0.79-1.13), respectively. Respective HRs (95% CIs) for HF readmission were 1.65 (0.97-2.80), 1.18 (0.90-1.56) and 1.09 (0.88-1.35).
546			_aEnglish
650			_aIN PROCESS -- NOT YET INDEXED
651			_aMedStar Heart & Vascular Institute
651			_aMedStar Washington Hospital Center
656			_aClinical Cardiac Electrophysiology Fellowship
657			_aJournal Article
700			_aLam, Phillip H
700			_aSheikh, Farooq H
700			_aTsimploulis, Apostolos _bMWHC _cClinical Cardiac Electrophysiology Fellowship _dMD _eFellow PGY 8
790			_aAhmed A, Allman RM, Aronow WS, Arundel C, Banerjee SK, Deedwania P, Faselis C, Fonarow GC, Lam PH, Patel S, Raman VK, Sheikh FH, Tsimploulis A
856			_uhttps://dx.doi.org/10.1016/j.pcad.2022.06.009 _zhttps://dx.doi.org/10.1016/j.pcad.2022.06.009
942			_cART _dArticle
999			_c393 _d393